Innovation Management in AI Development: Transforming Healthcare and Biopharma
Itohanosa Omolara Osarhiemen
School of Public Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
Boluwatife Samuel Awe
School of Public Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
Modupe Oluwatemitope Oyedele
School of Public Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
Ufuomanefe Cleopatra Omoemu *
School of Public Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
Konstantin Koshechkin
Institute of Digital Health, First Moscow State Medical University named after I.M. Sechenov, Moscow, Russia.
*Author to whom correspondence should be addressed.
Abstract
Artificial Intelligence (AI) is transforming healthcare and biopharmaceutical industries by revolutionizing diagnostics, personalizing medicine, and accelerating drug discovery. This study examines the critical role of innovation management in integrating AI technologies to drive value creation in these sectors. Through a comprehensive review of literature from 2017 to 2025, including peer-reviewed articles, industry reports, and case studies, we explore the applications, challenges, and opportunities of AI in healthcare and biopharma. The findings reveal that AI has the potential to significantly enhance diagnostic accuracy, streamline clinical trials, and reduce the time and cost of drug development. For instance, AI-powered tools like machine learning algorithms are improving disease detection through advanced imaging, while predictive analytics are enabling personalized treatment plans based on genetic and clinical data. In biopharma, AI is accelerating drug discovery by identifying potential drug candidates and optimizing clinical trial designs, as demonstrated by platforms like Atomwise and Insilico Medicine. However, the integration of AI into healthcare and biopharma is not without challenges. Ethical considerations, data privacy concerns, and the need for robust regulatory frameworks remain significant barriers. Issues such as algorithmic bias, the "black box" problem, and the lack of standardized data further complicate AI adoption. Effective innovation management is essential to address these challenges, ensuring that AI technologies are deployed ethically and efficiently. Strategies such as public-private partnerships, capacity building, and the development of open-source AI solutions are crucial for scaling AI in low- and middle-income countries (LMICs), where healthcare disparities are most pronounced. By addressing these challenges, AI can drive transformative advancements in patient care, therapeutic development, and global health equity, paving the way for a more efficient, personalized, and inclusive healthcare ecosystem.
Keywords: Biopharmaceuticals, diagnostics, personalized medicine, drug discovery, ethical considerations, regulatory compliance